uniQure/$QURE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About uniQure
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
- Ticker
- $QURE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 221
- Headquarters
- Amsterdam, Netherlands
- Website
- www.uniqure.com
uniQure Metrics
BasicAdvanced
$1.5B
-
-$3.56
-
-
Price and volume
Market cap
$1.5B
52-week high
$51.72
52-week low
$8.73
Average daily volume
3.2M
Financial strength
Current ratio
11.515
Quick ratio
11.195
Long term debt to equity
1.889
Total debt to equity
1.899
Interest coverage (TTM)
-3.49%
Profitability
EBITDA (TTM)
-184.783
Gross margin (TTM)
-119.01%
Net profit margin (TTM)
-1,154.84%
Operating margin (TTM)
-997.01%
Effective tax rate (TTM)
0.39%
Revenue per employee (TTM)
$90,000
Management effectiveness
Return on assets (TTM)
-13.74%
Return on equity (TTM)
-88.99%
Valuation
Price to revenue (TTM)
68.076
Price to book
4.99
Price to tangible book (TTM)
7.07
Price to free cash flow (TTM)
-7.115
Free cash flow yield (TTM)
-14.05%
Free cash flow per share (TTM)
-2.953
Growth
Revenue change (TTM)
28.04%
Earnings per share change (TTM)
-17.98%
3-year revenue growth (CAGR)
-43.51%
10-year revenue growth (CAGR)
0.11%
3-year earnings per share growth (CAGR)
-9.55%
10-year earnings per share growth (CAGR)
1.49%
What the Analysts think about uniQure
Analyst ratings (Buy, Hold, Sell) for uniQure stock.
Analyst projections of the future price of uniQure stock.
Bulls say / Bears say
The FDA agreed that AMT-130’s existing data could support an accelerated-approval application, and uniQure submitted its US application in September. It also filed in the UK, giving the programme more than one regulatory route. (SEC, BioPharma Dive)
At 36 months, the expanded high-dose group showed 80% slower progression on the main composite measure and 67% slower decline in daily function versus external controls. These results add support to the efficacy case behind the application. (uniQure)
Cash and investments of $810 million at the end of June were expected to fund operations into 2030. That gives uniQure time to run the confirmatory study and prepare for a possible launch without an immediate need to raise more capital. (uniQure)
At 48 months, the main composite measure showed 44% slower progression, but the result was not statistically significant. The result raises questions about how durable the apparent benefit is over time. (BioPharma Dive)
The longer-term efficacy case relies on small Phase I/II groups compared with patients in an observational database, not a concurrent randomised control group. Such comparisons cannot rule out unmeasured differences between the treated patients and the controls. (Medscape)
AMT-130 is delivered through invasive brain surgery, and five high-dose participants experienced treatment-related serious events involving central nervous system inflammation. The events resolved, but they underline the risks of a one-off procedure with limited patient exposure so far. (uniQure, MedicalDaily)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
uniQure Financial Performance
Revenues and expenses
uniQure Earnings Performance
Company profitability
Upcoming events
No upcoming events
uniQure News
AllArticlesVideos
uniQure Q3 Earnings Call Highlights
MarketBeat2 days ago
FDA Pushes uniQure Huntington Therapy Forward, Analyst Brushes Off Softening Signals
Benzinga4 days ago
uniQure N.V. Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your QURE Investments
Newsfile Corp3 weeks ago
Funds containing uniQure
Fund name | Fund size | $QURE weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.12% |
iShares Ageing Population£AGES | $953M | 0.12% |
iShares Ageing Population€AGED | $903M | 0.12% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.10% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.